Nanobiotix Announces Temporary Trading Halt of Its Ordinary Shares on Euronext Paris
The company said the halt will let it confirm investor allocations and price a global offering of about $87 million.
- On Thursday, May 21, 2026, Nanobiotix announced an approximately $87 million global follow-on offering, prompting a temporary trading halt of its ordinary shares on Euronext Paris.
- The offering consists of a U.S. public offering of American Depositary Shares and an international offering of ordinary shares and pre-funded warrants exclusively for qualified investors in Europe and other countries.
- Global coordinators Jefferies, TD Cowen, and Stifel are managing the sale, with pricing based on the volume-weighted average price of ordinary shares on Euronext over the previous three trading sessions, subject to a 15% discount.
- Trading on Euronext Paris is expected to resume today at approximately 3:30 p.m., while proceeds will support development of JNJ-1900, Nanoprimer platforms, and general corporate purposes.
- Executive and supervisory board members face a 90-day lock-up following pricing, while the company warns investors of potential share capital dilution and volatility in its ordinary shares and ADSs.
17 Articles
17 Articles
Hastings Tribune
Nanobiotix Announces Launch of Global Follow-On Offering
PARIS and CAMBRIDGE, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major…
Nanobiotix Announces Launch of Global Follow-On Offering - Nanobiotix (NASDAQ:NBTX)
PARIS and CAMBRIDGE, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ:NBTX – "Nanobiotix" or the "Company"), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announces the launch, subject to market and other conditions, of an approximately €75 million global follow-on offering (representing approximately …
Nanobiotix Announces Trading Resumption of Its Ordinary Shares on Euronext Paris
PARIS and CAMBRIDGE, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major…
Days after J&J update, Nanobiotix pauses trading amid €75M stock offering - European Biotechnology Magazine
Nanobiotix has temporarily paused trading of its shares in Europe while it prices the €75 million stock offering it launched in the wake of new data on its Johnson & Johnson-partnered lung cancer prospect. The post Days after J&J update, Nanobiotix pauses trading amid €75M stock offering appeared first on European Biotechnology Magazine.
The biotechnology company raises the equivalent of €85 million to significantly extend its cash horizon.
Coverage Details
Bias Distribution
- 67% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
